With the global technical textiles market heading toward $200B by 2030 , KBLB’s timing could enable early adoption and prototype work for 2026 procurement cycles, especially in high-performance and ...

Scribe Therapeutics Inc. ("Scribe"), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective enough to become standard-of-care ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...